Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Get Free Report) saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 500 shares, an increase of 25.0% from the May 15th total of 400 shares. Based on an average daily volume of 342,700 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the shares of the stock are sold short.
Scinai Immunotherapeutics Stock Performance
SCNI stock opened at $2.27 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.32 and a quick ratio of 1.32. Scinai Immunotherapeutics has a 12 month low of $1.90 and a 12 month high of $8.92. The firm’s 50-day moving average is $2.53 and its 200 day moving average is $3.04. The company has a market capitalization of $2.27 million, a PE ratio of -0.24 and a beta of 2.10.
Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($10.40) earnings per share (EPS) for the quarter. The business had revenue of $0.21 million for the quarter.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
See Also
- Five stocks we like better than Scinai Immunotherapeutics
- Investing in the High PE Growth Stocks
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- Most active stocks: Dollar volume vs share volume
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- What Are the FAANG Stocks and Are They Good Investments?
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.